TickerFacts.

Cullinan Therapeutics, Inc. (CGEM): Operating Income

Annual figures by period end, from SEC filings.

-$241.65M
Year ended 2025-12-31
-$221.81M
Trailing 12 months to 2026-06-30
$144.65M2020-12-31: -$60.34M2021-12-31: -$67.95M2022-12-31: $144.65M2023-12-31: -$191.09M2024-12-31: -$196.92M2025-12-31: -$241.65M-$241.65M
2020-12-31 Operating Income (USD) 2025-12-31
Period endedOperating IncomeChange YoYSource filing
2025-12-31-$241.65Mn/m2026-03-10, From 2025-01-01
2024-12-31-$196.92Mn/m2026-03-10, From 2024-01-01
2023-12-31-$191.09Mn/m2025-02-27, From 2023-01-01
2022-12-31$144.65Mn/m2024-03-14, From 2022-01-01
2021-12-31-$67.95Mn/m2023-03-09, From 2021-01-01
2020-12-31-$60.34Mn/a2022-03-17, From 2020-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating IncomeChange YoY
Cullinan Therapeutics, Inc. (CGEM)2025-12-31-$241.65Mn/m
Monte Rosa Therapeutics, Inc. (GLUE)2025-12-31-$54.21Mn/m
REGENXBIO Inc. (RGNX)2025-12-31-$161.20Mn/m
Vor Biopharma Inc. (VOR)2025-12-31-$371.64Mn/m
Sana Biotechnology, Inc. (SANA)2025-12-31-$250.32Mn/m
Allogene Therapeutics, Inc. (ALLO)2025-12-31-$209.31Mn/m
Vericel Corp (VCEL)2025-12-31$11.04M+144.4%
Scholar Rock Holding Corp (SRRK)2025-12-31-$384.64Mn/m
ImmunityBio, Inc. (IBRX)2025-12-31-$256.03Mn/m

Compare CGEM, GLUE, RGNX, VOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗